An overview of interventions in drug-induced weight gain during clozapine treatment

Weight gain associated with antidepressant therapy is a common problem that often results in noncompliance. Some authors suggest that monoamine oxidase inhibitors (MAOI) are less likely to produce weight gain than tricyclic antidepressants. This paper addresses the relative potential for weight gain with the MAOI. Assessing the potential for antidepressant-induced weight gain necessitates separating the weight changes associated with alterations in mood disorders from those due to drug-induced alterations in appetite control. The mechanisms of appetite control are reviewed briefly followed by proposed mechanisms by which the MAOI may alter this control. A literature review suggests that phenelzine is the MAOI most likely to induce weight gain; reports of isocarboxazid-induced weight gain are less common. There are no cases of tranylcypromine-induced weight gain in the literature that are clearly associated with the drug. The MAOI probably have different effects on the mechanisms of appetite control.

Download Full-text

PS20 - 95. Antipsychotic drug induced weight gain and insulin resistance: personality as a risk factor

Nederlands Tijdschrift voor Diabetologie ◽

10.1007/s12467-012-0129-5 ◽

2012 ◽

Vol 10 (3) ◽

pp. 166-167

Author(s):

Simon Evers ◽

Marianne Adema ◽

Jacolien Graver ◽

Gertjan van Dijk ◽

Anton Scheurink

Keyword(s):

Insulin Resistance ◽

Risk Factor ◽

Weight Gain ◽

Antipsychotic Drug ◽

Drug Induced

Download Full-text

Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients

Clinical Epigenetics ◽

10.1186/s13148-019-0792-0 ◽

2019 ◽

Vol 11 (1) ◽

Cited By ~ 1

Author(s):

Aurélie Delacrétaz ◽

Anaïs Glatard ◽

Céline Dubath ◽

Mehdi Gholam-Rezaee ◽

Jose Vicente Sanchez-Mut ◽

...

Keyword(s):

Weight Gain ◽

Side Effects ◽

Prospective Study ◽

Psychotropic Drugs ◽

Energy Homeostasis ◽

Psychiatric Patients ◽

Metabolic Disturbances ◽

Drug Induced ◽

Metabolic Side Effects ◽

Early Weight Gain

Abstract Background Metabolic side effects induced by psychotropic drugs represent a major health issue in psychiatry. CREB-regulated transcription coactivator 1 (CRTC1) gene plays a major role in the regulation of energy homeostasis and epigenetic mechanisms may explain its association with obesity features previously described in psychiatric patients. This prospective study included 78 patients receiving psychotropic drugs that induce metabolic disturbances, with weight and other metabolic parameters monitored regularly. Methylation levels in 76 CRTC1 probes were assessed before and after 1 month of psychotropic treatment in blood samples. Results Significant methylation changes were observed in three CRTC1 CpG sites (i.e., cg07015183, cg12034943, and cg 17006757) in patients with early and important weight gain (i.e., equal or higher than 5% after 1 month; FDR p value = 0.02). Multivariable models showed that methylation decrease in cg12034943 was more important in patients with early weight gain (≥ 5%) than in those who did not gain weight (p = 0.01). Further analyses combining genetic and methylation data showed that cg12034943 was significantly associated with early weight gain in patients carrying the G allele of rs4808844A>G (p = 0.03), a SNP associated with this methylation site (p = 0.03). Conclusions These findings give new insights on psychotropic-induced weight gain and underline the need of future larger prospective epigenetic studies to better understand the complex pathways involved in psychotropic-induced metabolic side effects.

Download Full-text